Drugs in Dev. Immunology
Phase I
Taiwan 
Lead Product(s) : MS-20,Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Microbio's "MS-20" Shows Promise as Add-On Therapy for Ulcerative Colitis
Details : MS-20 is a postbiotic produced through the symbiotic fermentation of multi-strain probiotics. It is being investigated for immunological and gastrointestinal diseases.
Product Name : MS-20
Product Type : Probiotic
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : MS-20,Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab
Details : Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $3.0 million
April 29, 2020
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Reset All
